Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 3:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer Tumor Clear all
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer

NCT00159484
View directory record Official record
Conditions
Colon Cancer, Colorectal Cancer
Interventions
EPO906, Celecoxib
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Not applicable Interventional

Impact of a Novel Patient Educational Booklet on Colonoscopy Quality

NCT00975247
View directory record Official record
Conditions
Colon Cancer, Colonoscopy
Interventions
Receiving an educational booklet
Other
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

NCT01261247
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
panobinostat, laboratory biomarker analysis, western blotting, DNA analysis, flow cytometry, pharmacological study, immunohistochemistry staining method
Drug · Other · Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vitamin D Plus Celecoxib Therapy to Stimulate Intratumoral Immune Reactivity

NCT00953849
View directory record Official record
Conditions
Mouth Neoplasms
Interventions
Celecoxib, Calcitriol, Celecoxib plus Calcitriol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer

NCT00005049
View directory record Official record
Conditions
Colorectal Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Ovarian Cancer, Peritoneal Cavity Cancer, Small Intestine Cancer
Interventions
carboplatin, cisplatin, floxuridine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2011 · Synced Sep 28, 2026, 3:49 PM EDT
Terminated Phase 1 Interventional

Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

NCT00311558
View directory record Official record
Conditions
Cancer
Interventions
recombinant interferon alfa-2b, sodium stibogluconate, SSG & interferon
Biological · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Sep 28, 2026, 3:49 PM EDT
Withdrawn Not applicable Interventional

Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

NCT06603155
View directory record Official record
Conditions
Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions
Time restricted eating (TRE)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 28, 2026, 3:49 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

NCT04452955
View directory record Official record
Conditions
Solid Tumor
Interventions
PRL3-zumab
Biological
Lead sponsor
Intra-IMMUSG Pte Ltd
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 3:49 PM EDT
Recruiting Phase 1 Interventional

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

NCT07456878
View directory record Official record
Conditions
Pituitary Adenoma
Interventions
FET-PET/MRI
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 28, 2026, 3:49 PM EDT
Terminated Phase 2 Interventional Results available

Cvac as Maintenance Treatment in Patients With Epithelial Ovarian Cancer in Complete Remission Following First-line Chemotherapy or Second-line Treatment

NCT01521143
View directory record Official record
Conditions
Epithelial Ovarian Cancer
Interventions
Cvac, Placebo
Biological
Lead sponsor
Prima BioMed Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
6
States / cities
Los Angeles, California • Boynton Beach, Florida • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2016 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

NCT03801915
View directory record Official record
Conditions
Colon Cancer, Pancreatic Cancer, Cholangiocarcinoma, Metastatic Colon Carcinoma, Liver Metastasis
Interventions
MVT-5873, pancreatectomy or hepatectomy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Locally Advanced NSCLC Hyperfractionated RT

NCT03128008
View directory record Official record
Conditions
Carcinoma, Non Small Cell Lung (NSCLC)
Interventions
Carboplatin, Paclitaxel, Daily hyperfractionated radiation therapy
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Sep 28, 2026, 3:49 PM EDT
Completed No phase listed Observational

Genetic Investigation of Solid Tumors Cohort

NCT01005225
View directory record Official record
Conditions
Prostate Cancer, Colon Cancer
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Sep 28, 2026, 3:49 PM EDT
Active, not recruiting Not applicable Interventional

Technology-Enabled Activation of Skin Cancer Screening for Stem Cell Transplant Survivors and Their Primary Care Providers, TEACH Study

NCT04358276
View directory record Official record
Conditions
Skin Carcinoma
Interventions
Computer-Assisted Intervention, Dermatoscope, Educational Intervention, Educational Intervention (Physician), Questionnaire Administration, Text Message
Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 28, 2026, 3:49 PM EDT
Withdrawn Phase 3 Interventional

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NCT00576225
View directory record Official record
Conditions
NSCLC
Interventions
CT-2103/carboplatin, paclitaxel/carboplatin
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
44
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Burbank, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia

NCT03692325
View directory record Official record
Conditions
Leukoplakia, Oral
Interventions
Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

NCT00217425
View directory record Official record
Conditions
Lymphoma
Interventions
bevacizumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
110
States / cities
Greenbrae, California • Palo Alto, California • Fort Collins, Colorado + 77 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 28, 2026, 3:49 PM EDT
Active, not recruiting Phase 1 Interventional Results available

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

NCT03300817
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
55 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of Oral TP-1454

NCT04328740
View directory record Official record
Conditions
Advanced Solid Tumor, Anal Cancer
Interventions
TP-1454 monotherapy
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer

NCT00057889
View directory record Official record
Conditions
Kidney Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 28, 2026, 3:49 PM EDT
Completed Phase 1 Interventional

Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

NCT01445405
View directory record Official record
Conditions
Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
Interventions
Bortezomib (Velcade, PS-341), Cetuximab, Cisplatin, Radiation Therapy
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 28, 2026, 3:49 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial to Assess the Effects of Green Tea in Oral Leukoplakia

NCT00176566
View directory record Official record
Conditions
Oral Leukoplakia
Interventions
Lozenge Intake
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2009 · Synced Sep 28, 2026, 3:49 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma

NCT02147951
View directory record Official record
Conditions
Unresected Stage IIIb to IVM1c Melanoma
Interventions
Talimogene Laherparepvec
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 95 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Mobile, Alabama • Little Rock, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Sep 28, 2026, 3:49 PM EDT
Active, not recruiting Phase 2 Interventional Results available

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

NCT02392429
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chemotherapy, Computed Tomography, Cytarabine, Fluorothymidine F-18, Laboratory Biomarker Analysis, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
11
States / cities
Rochester, Minnesota • St Louis, Missouri • New York, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 28, 2026, 3:49 PM EDT